Hepatitis Monthly

Published by: Kowsar

Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV

Sara Ashtari 1 , Mohsen Vahedi 2 , Mohammad Amin Pourhoseingholi 1 , * , Maryam Karkhane 1 , Zahra Kimiia 1 , Asma Pourhoseingholi 1 , Azadeh Safaee 3 , Bijan Moghimi-Dehkordi 3 , Mohammad Reza Zali 1 and Seyed Moayed Alavian 4
Authors Information
1 Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Science, Tehran, IR Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Disease Control and Prevention, Deputy of Health, Shahid Beheshti University of Medical Science, Tehran, IR Iran
4 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: April 01, 2013, 13 (5); e8415
  • Published Online: April 28, 2013
  • Article Type: Research Article
  • Received: October 6, 2012
  • Revised: December 26, 2012
  • Accepted: February 18, 2013
  • DOI: 10.5812/hepatmon.8415

To Cite: Ashtari S, Vahedi M, Pourhoseingholi M A, Karkhane M, Kimiia Z, et al. Direct Medical Care Costs Associated With Patients Diagnosed With Chronic HCV, Hepat Mon. 2013 ; 13(5):e8415. doi: 10.5812/hepatmon.8415.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Alavian SM. We need a new national approach to control hepatitis C: It is becoming too late. Hepat Mon. 2008; 8(3): 165-9[PubMed]
  • 2. Alavian SM. Hepatitis C infection in Iran; A review article. Iran J Clin Infect Dis. 2009; 4(1): 47-59
  • 3. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41[PubMed]
  • 4. Brown RSJr, Gaglio PJ. Scope of worldwide hepatitis C problem. Liver Transpl. 2003; 9(11)-3[PubMed]
  • 5. Alavian SM, Lankarani KB, Alaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of chronic hepatitis C Infection: Updated of the Recommendation from Scientific Leaders' Meeting-28th July 2011-tehran, IR iRAN. Hepat Mon. 2011; 11(9): 703-13
  • 6. Alavian SM, Ahmadzad Asl M, Lankarani KB, Shahbabaie MA, Bahrami Ahmadi A, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. Hepat Mon. 2009; 9(3): 211-23
  • 7. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[PubMed]
  • 8. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 9. Williams R. Global challenges in liver disease. Hepatology. 2006; 44(3): 521-6[PubMed]
  • 10. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26(3): 34S-8S[PubMed]
  • 11. El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ. 2005; 6(2): 159-65[PubMed]
  • 12. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. Gastro Hepat. 2010; 3(1): 5-14
  • 13. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[PubMed]
  • 14. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006; 101(9): 2076-89[PubMed]
  • 15. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001; 161(18): 2231-7[PubMed]
  • 16. Dienstag JL, Isselbacher KJ. Harrison's principles of internal medicine. 2005;
  • 17. Kenneth W, Lin MD, Jeffrey T, Kirchner DO. Lancaster, American Family Physicisn. Pennsylvania. 2004; 69: 75-82
  • 18. Rice DP. Cost of illness studies: what is good about them? Inj Pre. 2000; 6(3): 175-6
  • 19. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009; 50(2): 407-13[PubMed]
  • 20. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8(2): 192-9[PubMed]
  • 21. Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. Hepat Mon. 2003; 5(3): 77-82
  • 22. Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon alpha-2a AND alpha-2b in patients with genotype 1 chronic Hepatitis C: a meta-analysis. BMC Infect Dis. 2012; 12(1): 357[PubMed]
  • 23. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000; 31(1): 211-8[PubMed]
  • 24. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003; 362(9401): 2095-100[PubMed]
  • 25. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[PubMed]
  • 26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4): 1147-71[PubMed]
  • 27. Center for Disease Control and Prevention. Cost analysis: Introduction/CDC Econ Eval Tutorials.
  • 28. Moghimi-Dehkordi B, Vahedi M, Khoshkrood Mansoori B, Kasaeian A, Safaee A, Habibi M, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. Arab J Gastroenterol. 2011; 12(2): 86-9[PubMed]
  • 29. Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi MA, Khoshkrood Mansoori B, Safaee A, Habibi M, et al. Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study. J Dig Dis. 2011; 12(5): 384-92[PubMed]
  • 30. Mohaghegh Shalmani H, Soori H, Khoshkrood Mansoori B, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi MA, et al. Direct and indirect medical costs of functional constipation: a population-based study. Int J Colorectal Dis. 2011; 26(4): 515-22[PubMed]
  • 31. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis. 2007; 22(7): 791-9[PubMed]
  • 32. Medical Laws and Tariffs. [The price list by Iranian Cabinet of the Public Health Centers]. 2010;
  • 33. Iranian Ministry of Health and Medical Education. [List of price of drugs]. 2010;
  • 34. Trading Economic Website. 2010;
  • 35. Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. Hepat Mon. 2009; 9(2): 95-102[PubMed]
  • 36. Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis. 2011; 2(1): 39-45[PubMed]
  • 37. Iranian Databases of Census Publication. 2006;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments